Cargando…

Co-treatment of gonadotropin and letrozole in infertile women with endometriosis: A double-blind randomized clinical trial

BACKGROUND: The common causes of infertility in women with endometriosis are folliculogenesis alternation, steroidogenesis and fertilization impairment, oocyte and embryo quality reduction, and implantation defect. OBJECTIVE: To compare in vitro fertilization (IVF) cycle success rates of women with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebrahimi, Mahbod, Akbari Asbagh, Firoozeh, Davari Tanha, Fatemeh, Pakniat, Hamideh, Feizabad, Elham, Rasouli, Yasin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Knowledge E 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358235/
https://www.ncbi.nlm.nih.gov/pubmed/35958963
http://dx.doi.org/10.18502/ijrm.v20i6.11444
_version_ 1784763885010550784
author Ebrahimi, Mahbod
Akbari Asbagh, Firoozeh
Davari Tanha, Fatemeh
Pakniat, Hamideh
Feizabad, Elham
Rasouli, Yasin
author_facet Ebrahimi, Mahbod
Akbari Asbagh, Firoozeh
Davari Tanha, Fatemeh
Pakniat, Hamideh
Feizabad, Elham
Rasouli, Yasin
author_sort Ebrahimi, Mahbod
collection PubMed
description BACKGROUND: The common causes of infertility in women with endometriosis are folliculogenesis alternation, steroidogenesis and fertilization impairment, oocyte and embryo quality reduction, and implantation defect. OBJECTIVE: To compare in vitro fertilization (IVF) cycle success rates of women with endometriosis who were treated with letrozole + gonadotropin (LA) vs. placebo + gonadotropin (PA). MATERIALS AND METHODS: This double-blind, randomized clinical trial study was conducted with 94 infertile women with endometriosis (47 in the LA group and 47 in the PA group) who were candidates for IVF, from April-June 2021. For all participants, the long agonist protocol was applied. In both groups, gonadotropin-releasing hormone agonist was prescribed in the mid-luteal stage and from the third day of the cycle, and gonadotropin was started and its doses were regulated based on the patient's age, serum anti-Mullerian hormone and follicle-stimulating hormone. From the third day of the menstrual cycle, 5 mg of letrozole daily for 5 days was prescribed for the LA group, while the placebo was prescribed for the PA group on the identical days and duration. After embryo transfer, biochemical and clinical pregnancy were measured in the 2 groups. RESULTS: The gonadotropin dosage (p [Formula: see text] 0.01) and estradiol level (p = 0.02) on the human chorionic gonadotropin administration day were significantly lower in the LA group compared with in the PA group. Fetus transfer was done for 32 women. No significant differences were detected between the study groups regarding biochemical or clinical pregnancy (p = 0.72 for both). CONCLUSION: Letrozole as a co-treatment drug in the IVF cycle of women with endometriosis can significantly reduce the gonadotropin dosage and estradiol level with the same pregnancy rates.
format Online
Article
Text
id pubmed-9358235
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Knowledge E
record_format MEDLINE/PubMed
spelling pubmed-93582352022-08-10 Co-treatment of gonadotropin and letrozole in infertile women with endometriosis: A double-blind randomized clinical trial Ebrahimi, Mahbod Akbari Asbagh, Firoozeh Davari Tanha, Fatemeh Pakniat, Hamideh Feizabad, Elham Rasouli, Yasin Int J Reprod Biomed Original Article BACKGROUND: The common causes of infertility in women with endometriosis are folliculogenesis alternation, steroidogenesis and fertilization impairment, oocyte and embryo quality reduction, and implantation defect. OBJECTIVE: To compare in vitro fertilization (IVF) cycle success rates of women with endometriosis who were treated with letrozole + gonadotropin (LA) vs. placebo + gonadotropin (PA). MATERIALS AND METHODS: This double-blind, randomized clinical trial study was conducted with 94 infertile women with endometriosis (47 in the LA group and 47 in the PA group) who were candidates for IVF, from April-June 2021. For all participants, the long agonist protocol was applied. In both groups, gonadotropin-releasing hormone agonist was prescribed in the mid-luteal stage and from the third day of the cycle, and gonadotropin was started and its doses were regulated based on the patient's age, serum anti-Mullerian hormone and follicle-stimulating hormone. From the third day of the menstrual cycle, 5 mg of letrozole daily for 5 days was prescribed for the LA group, while the placebo was prescribed for the PA group on the identical days and duration. After embryo transfer, biochemical and clinical pregnancy were measured in the 2 groups. RESULTS: The gonadotropin dosage (p [Formula: see text] 0.01) and estradiol level (p = 0.02) on the human chorionic gonadotropin administration day were significantly lower in the LA group compared with in the PA group. Fetus transfer was done for 32 women. No significant differences were detected between the study groups regarding biochemical or clinical pregnancy (p = 0.72 for both). CONCLUSION: Letrozole as a co-treatment drug in the IVF cycle of women with endometriosis can significantly reduce the gonadotropin dosage and estradiol level with the same pregnancy rates. Knowledge E 2022-07-06 /pmc/articles/PMC9358235/ /pubmed/35958963 http://dx.doi.org/10.18502/ijrm.v20i6.11444 Text en Copyright © 2022 Ebrahimi et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ebrahimi, Mahbod
Akbari Asbagh, Firoozeh
Davari Tanha, Fatemeh
Pakniat, Hamideh
Feizabad, Elham
Rasouli, Yasin
Co-treatment of gonadotropin and letrozole in infertile women with endometriosis: A double-blind randomized clinical trial
title Co-treatment of gonadotropin and letrozole in infertile women with endometriosis: A double-blind randomized clinical trial
title_full Co-treatment of gonadotropin and letrozole in infertile women with endometriosis: A double-blind randomized clinical trial
title_fullStr Co-treatment of gonadotropin and letrozole in infertile women with endometriosis: A double-blind randomized clinical trial
title_full_unstemmed Co-treatment of gonadotropin and letrozole in infertile women with endometriosis: A double-blind randomized clinical trial
title_short Co-treatment of gonadotropin and letrozole in infertile women with endometriosis: A double-blind randomized clinical trial
title_sort co-treatment of gonadotropin and letrozole in infertile women with endometriosis: a double-blind randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358235/
https://www.ncbi.nlm.nih.gov/pubmed/35958963
http://dx.doi.org/10.18502/ijrm.v20i6.11444
work_keys_str_mv AT ebrahimimahbod cotreatmentofgonadotropinandletrozoleininfertilewomenwithendometriosisadoubleblindrandomizedclinicaltrial
AT akbariasbaghfiroozeh cotreatmentofgonadotropinandletrozoleininfertilewomenwithendometriosisadoubleblindrandomizedclinicaltrial
AT davaritanhafatemeh cotreatmentofgonadotropinandletrozoleininfertilewomenwithendometriosisadoubleblindrandomizedclinicaltrial
AT pakniathamideh cotreatmentofgonadotropinandletrozoleininfertilewomenwithendometriosisadoubleblindrandomizedclinicaltrial
AT feizabadelham cotreatmentofgonadotropinandletrozoleininfertilewomenwithendometriosisadoubleblindrandomizedclinicaltrial
AT rasouliyasin cotreatmentofgonadotropinandletrozoleininfertilewomenwithendometriosisadoubleblindrandomizedclinicaltrial